Ewha Med J.  2017 Jul;40(3):104-107. 10.12771/emj.2017.40.3.104.

The Examination of Ovarian Reserve in Premenopausal Patients with Hormone Receptor Positive Breast Cancer

• Kim HA
• Woo J
• Choi HS
• Lee SJ
• Choi J
• Park CS
• Seong MK
• Noh WC

• KMID: 2386386
• DOI: http://doi.org/10.12771/emj.2017.40.3.104

Abstract

The evaluation of menopausal status is an important subject in the field of treatment of hormone receptor positive breast cancer. According to the menopausal status, endocrine therapy should be categorized by individual patient. However, the gonadal injury caused by various therapeutic drugs and its recovery would confuse the interpretation of clinical and biological markers for ovarian reserve. There are some methods to examine the functional ovarian reserve indirectly. Ultrasonography for counting follicles is a relatively reliable procedure, although it is not feasible because of time-labor consumption and high cost. Biological marker from blood samples such as serum follicle stimulating hormone (FSH), serum estradiol (E2), serum inhibin, or anti-Müllerian hormone (AMH) would be a better choice. The examination of serum FSH and E2 is already recommended as biomarkers for measuring functional ovarian reserve in many guidelines. However, there are limitation of serum FSH and E2 in patients with chemotherapy-induced amenorrhea and treated by tamoxifen. AMH is promising biomarker in the field of infertility treatment even in the patients treated by chemotherapy. It might be a possible biomarker to determine the menopausal status for decision-making whether aromatase inhibitor could be applicable or not in hormone positive breast cancer patients with chemotherapy induced amenorrhea or treated by tamoxifen.

Keyword

Breast neoplasms; Anti-Mullerian hormone; Premenopause; Receptors; Estrogen

MeSH Terms

Amenorrhea
Anti-Mullerian Hormone
Aromatase
Biomarkers
Breast Neoplasms*
Breast*
Drug Therapy
Estradiol
Estrogens
Female
Follicle Stimulating Hormone
Gonads
Humans
Infertility
Inhibins
Ovarian Reserve*
Premenopause
Tamoxifen
Ultrasonography
Anti-Mullerian Hormone
Aromatase
Biomarkers
Estradiol
Estrogens
Follicle Stimulating Hormone
Inhibins
Tamoxifen

Reference

1. Beatson GT. On the treatment of inoperable cases of carcinoma of the mamma: suggestions for a new method for treatment with illustrative cases. Lancet. 1896; 148:162–165.

2. Tryfonidis K, Zardavas D, Katzenellenbogen BS, Piccart M. Endocrine treatment in breast cancer: Cure, resistance and beyond. Cancer Treat Rev. 2016; 50:68–81.

3. Krekow LK, Hellerstedt BA, Collea RP, Papish S, Diggikar SM, Resta R, et al. Incidence and predictive factors for recovery of ovarian function in amenorrheic women in their 40s treated with letrozole. J Clin Oncol. 2016; 34:1594–1600.

4. Park EH, Min SY, Kim Z, Yoon CS, Jung KW, Nam SJ, et al. Basic facts of breast cancer in Korea in 2014: the 10-year overall survival progress. J Breast Cancer. 2017; 20:1–11.

5. National Comprehensive Cancer Network (NCCN). NCCN Guidelines [Internet]. Fort Washington, PA: NCCN;c2017. cited 2017 Jul 4. https://www.nccn.org/professionals/physician_gls/f_guidelines.asp.

6. Wallace WH, Anderson RA, Irvine DS. Fertility preservation for young patients with cancer: who is at risk and what can be offered. Lancet Oncol. 2005; 6:209–218.

7. Ben-Haroush A, Farhi J, Zahalka Y, Sapir O, Meizner I, Fisch B. Correlations between antral follicle count and ultrasonographic ovarian parameters and clinical variables and outcomes in IVF cycles. Gynecol Endocrinol. 2012; 28:432–435.

8. Visser JA, Schipper I, Laven JS, Themmen AP. Anti-Müllerian hormone: an ovarian reserve marker in primary ovarian insufficiency. Nat Rev Endocrinol. 2012; 8:331–341.

9. Meczekalski B, Czyzyk A, Kunicki M, Podfigurna-Stopa A, Plociennik L, Jakiel G, et al. Fertility in women of late reproductive age: the role of serum anti-Müllerian hormone (AMH) levels in its assessment. J Endocrinol Invest. 2016; 39:1259–1265.

10. La Marca A, Stabile G, Artenisio AC, Volpe A. Serum anti-Mullerian hormone throughout the human menstrual cycle. Hum Reprod. 2006; 21:3103–3107.

11. Lee TH, Liu CH, Huang CC, Hsieh KC, Lin PM, Lee MS. Impact of female age and male infertility on ovarian reserve markers to predict outcome of assisted reproduction technology cycles. Reprod Biol Endocrinol. 2009; 7:100.

12. Su HI, Flatt SW, Natarajan L, DeMichele A, Steiner AZ. Impact of breast cancer on anti-mullerian hormone levels in young women. Breast Cancer Res Treat. 2013; 137:571–577.

13. Bozza C, Puglisi F, Lambertini M, Osa EO, Manno M, Del Mastro L. Anti-Mullerian hormone: determination of ovarian reserve in early breast cancer patients. Endocr Relat Cancer. 2014; 21:R51–R65.

14. Anderson RA, Cameron DA. Pretreatment serum anti-Müllerian hormone predicts long-term ovarian function and bone mass after chemotherapy for early breast cancer. J Clin Endocrinol Metab. 2011; 96:1336–1343.

15. Kim HA, Seong MK, Kim JH, Kim YG, Choi HS, Kim JS, et al. Prognostic value of anti-Müllerian hormone and inhibin B in patients with premenopausal hormone receptor-positive breast cancer. Anticancer Res. 2016; 36:1051–1057.

16. Su HI, Sammel MD, Green J, Velders L, Stankiewicz C, Matro J, et al. Antimullerian hormone and inhibin B are hormone measures of ovarian function in late reproductive-aged breast cancer survivors. Cancer. 2010; 116:592–599.